JP2022554277A5 - - Google Patents

Info

Publication number
JP2022554277A5
JP2022554277A5 JP2022525291A JP2022525291A JP2022554277A5 JP 2022554277 A5 JP2022554277 A5 JP 2022554277A5 JP 2022525291 A JP2022525291 A JP 2022525291A JP 2022525291 A JP2022525291 A JP 2022525291A JP 2022554277 A5 JP2022554277 A5 JP 2022554277A5
Authority
JP
Japan
Prior art keywords
composition according
composition
reduction
treatment
determined
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022525291A
Other languages
English (en)
Japanese (ja)
Other versions
JP7664239B2 (ja
JP2022554277A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/058411 external-priority patent/WO2021087399A1/en
Publication of JP2022554277A publication Critical patent/JP2022554277A/ja
Publication of JP2022554277A5 publication Critical patent/JP2022554277A5/ja
Priority to JP2025063020A priority Critical patent/JP2025106418A/ja
Application granted granted Critical
Publication of JP7664239B2 publication Critical patent/JP7664239B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022525291A 2019-10-30 2020-10-30 エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 Active JP7664239B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025063020A JP2025106418A (ja) 2019-10-30 2025-04-07 エンドセリンレセプターアンタゴニストを使用する眼疾患の処置

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962928092P 2019-10-30 2019-10-30
US62/928,092 2019-10-30
US202063068215P 2020-08-20 2020-08-20
US63/068,215 2020-08-20
PCT/US2020/058411 WO2021087399A1 (en) 2019-10-30 2020-10-30 Treatment of ocular diseases using endothelin receptor antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025063020A Division JP2025106418A (ja) 2019-10-30 2025-04-07 エンドセリンレセプターアンタゴニストを使用する眼疾患の処置

Publications (3)

Publication Number Publication Date
JP2022554277A JP2022554277A (ja) 2022-12-28
JP2022554277A5 true JP2022554277A5 (enExample) 2023-11-07
JP7664239B2 JP7664239B2 (ja) 2025-04-17

Family

ID=75715356

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022525291A Active JP7664239B2 (ja) 2019-10-30 2020-10-30 エンドセリンレセプターアンタゴニストを使用する眼疾患の処置
JP2025063020A Pending JP2025106418A (ja) 2019-10-30 2025-04-07 エンドセリンレセプターアンタゴニストを使用する眼疾患の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025063020A Pending JP2025106418A (ja) 2019-10-30 2025-04-07 エンドセリンレセプターアンタゴニストを使用する眼疾患の処置

Country Status (9)

Country Link
US (5) US20220257505A1 (enExample)
EP (2) EP4050997A4 (enExample)
JP (2) JP7664239B2 (enExample)
CN (2) CN114786480B (enExample)
AU (1) AU2020373065A1 (enExample)
CA (1) CA3158767A1 (enExample)
IL (1) IL292350A (enExample)
MX (1) MX2022005063A (enExample)
WO (1) WO2021087399A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
EP4050997A4 (en) 2019-10-30 2022-11-30 Perfuse Therapeutics, Inc. TREATMENT OF EYE DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS
CA3168810A1 (en) 2020-02-06 2021-08-12 Perfuse Therapeutics, Inc. Compositions for treatment of ocular diseases
CA3218398A1 (en) * 2021-04-30 2022-11-03 Perfuse Therapeutics, Inc. Treatment of ocular diseases using endothelin receptor antagonists
EP4329753A4 (en) * 2021-04-30 2025-02-26 Perfuse Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF EYE DISEASES
WO2022251710A2 (en) 2021-05-28 2022-12-01 Sight Sciences, Inc. Intraocular devices, systems, and methods
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4282793A (en) * 1992-04-10 1993-11-18 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A microneedle for injection of ocular blood vessels
US6162927A (en) 1994-08-19 2000-12-19 Abbott Laboratories Endothelin antagonists
JPH0959173A (ja) * 1995-08-21 1997-03-04 Santen Pharmaceut Co Ltd 毛様体筋緊張緩和剤
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
JP2004525890A (ja) * 2001-02-02 2004-08-26 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング ピラゾロ［４，３−ｄ］ピリミジンおよびエンドセリンレセプターアンタゴニストまたはチエノピリミジンおよびエンドセリンレセプターアンタゴニストを含む医薬製剤
US20030176356A1 (en) * 2001-04-24 2003-09-18 University Of North Texas Health Science Center Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma
GB0122318D0 (en) * 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US20070260203A1 (en) 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
EP2545920A1 (en) * 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Therapy for complications of diabetes
BRPI1013904A2 (pt) * 2009-04-30 2016-07-19 Univ Midwestern método e composição para tratar cetoacidose diabética
US20110082151A1 (en) 2009-06-12 2011-04-07 Auspex Pharmaceuticals, Inc. Sulfonylurea modulators of endothelin receptor
KR20130050939A (ko) * 2010-04-12 2013-05-16 가부시키가이샤 아루떼꾸 우에노 망막 질환의 치료 방법 및 이를 위한 안과용 조성물
MX390909B (es) * 2013-12-19 2025-03-21 Tassos Georgiou Composiciones de acidos grasos omega 3 para tratar enfermedades que implican daños al sistema nervioso.
ES2584534B1 (es) * 2015-03-27 2017-03-13 Retinset, S.L. Formulación tópica oftálmica de bosentan
CN107921036A (zh) * 2015-05-29 2018-04-17 优势医疗公司 用于减少视力丧失的组合物和方法
WO2017217967A1 (en) * 2016-06-13 2017-12-21 Noveome Biotherapeutics, Inc. Novel methods for delivering therapeutic agents to the eye via nasal passages
WO2018185516A1 (en) 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
EP3642214A2 (en) * 2017-06-19 2020-04-29 Gangadhara Ganapati Nicotinamide riboside derivatives and their uses
JP2020528082A (ja) * 2017-07-17 2020-09-17 ロイズマン，キース 加齢黄斑変性と他の眼疾患の治療用の細胞透過性ペプチドを使用する治療薬の局所送達
WO2019210194A1 (en) * 2018-04-26 2019-10-31 Vitrisa Therapeutics, Inc. Pegylated compositions for ocular use, and methods thereof
EP4050997A4 (en) 2019-10-30 2022-11-30 Perfuse Therapeutics, Inc. TREATMENT OF EYE DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS
CA3168810A1 (en) * 2020-02-06 2021-08-12 Perfuse Therapeutics, Inc. Compositions for treatment of ocular diseases
EP4329753A4 (en) 2021-04-30 2025-02-26 Perfuse Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF EYE DISEASES

Similar Documents

Publication Publication Date Title
Casson Medical therapy for glaucoma: A review
JP2022554277A5 (enExample)
Soltau et al. Changing paradigms in the medical treatment of glaucoma
JP6014033B2 (ja) 防腐剤無添加ビマトプロストおよびチモロール溶液
US10213431B2 (en) Preservative free brimonidine and timolol solutions
US20060111388A1 (en) Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye
IL292350A (en) Treatment of ocular diseases using endothelin receptor antagonists
Schellack et al. Glaucoma: a brief review
Ha et al. Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal‐tension glaucoma: the randomized phase II study
ES2210018T3 (es) Antagonistas de 5ht-2 para regular la presion intraocular y tratar el glaucoma.
Weinreb et al. Latanoprostene bunod, a dual-acting nitric oxide donating prostaglandin analog for lowering of intraocular pressure
WO2019024433A1 (zh) 氨基金刚烷胺单硝酸酯类化合物眼用组合物及其制剂和应用
WO2003004058A1 (fr) Agents de protection du nerf optique contenant un bloqueur de recepteur $g(a)1 en tant qu'ingredient actif
Miller-Ellis et al. Then and Now: Medical Therapy for Glaucoma
JP2024516829A5 (enExample)
Higginbotham Will latanoprost be the'wonder'drug of the'90s for the treatment of glaucoma?
Johansyah et al. Rho-kinase inhibitor: a potential alternative to current glaucoma therapy
US5563171A (en) Treatment of glaucoma and ocular hypertension with β3-adrenergic agonists
Kim et al. Medical Treatment of Glaucoma
KR20030063387A (ko) 망막 허혈에 기초하는 질환의 치료 및/또는 예방제
RENGARAJ VENKATESH COMMONLY PRESCRIBED GLAUCOMA EYE DROPS AND ORAL MEDICATIONS
Kanner et al. Adrenergic Agents
Realini et al. 19. The History of Glaucoma Medications
Dada et al. Medical Management of glaucoma
Tab Peridex, PerioGard Oral soln: 0.12%(480ml)